Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 7,069 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of Exercise on Sex Hormones in Postmenopausal Women

NCT00668174
View directory record Official record
Conditions
Breast Cancer Prevention
Interventions
Exercise
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 20, 2026, 5:28 AM EDT
Not listed Phase 1 Interventional

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

NCT03775525
View directory record Official record
Conditions
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
Interventions
GZ17-6.02, Capecitabine
Drug
Lead sponsor
Genzada Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 20, 2026, 5:28 AM EDT
Not listed Phase 2 Interventional

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

NCT00499525
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, sorafenib tosylate, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
43
States / cities
Muscle Shoals, Alabama • Fayetteville, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Not applicable Interventional

Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey

NCT03995082
View directory record Official record
Conditions
Breast Cancer, Patient Reported Outcomes
Interventions
Patient Reported Outcome Measure Survey result feedback
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Female only
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
3
States / cities
Denver, Colorado • Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice

NCT04763824
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
KanSurvive ECHO and Practice Facilitation
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

NCT04789668
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting Phase 1 Interventional

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

NCT05746897
View directory record Official record
Conditions
Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
Interventions
NM1F Injection, Pembrolizumab injection
Drug
Lead sponsor
Hefei TG ImmunoPharma Co., Ltd.
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Dallas, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00045097
View directory record Official record
Conditions
Breast Cancer
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 20, 2026, 5:28 AM EDT
Not listed Not applicable Interventional

Study of an Intervention to Improve Problem List Accuracy and Use

NCT01105923
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions
MAPLE
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NCT00464646
View directory record Official record
Conditions
Breast Cancer
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • San Diego, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Not applicable Interventional

Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer

NCT06019988
View directory record Official record
Conditions
Breast Cancer, Social Determinants of Health (SDOH)
Interventions
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

NCT05877859
View directory record Official record
Conditions
Breast Cancer Triple Negative, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

NCT06848348
View directory record Official record
Conditions
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Interventions
Halneuron, Placebo, Halneuron (Open Label Extension)
Drug
Lead sponsor
Dogwood Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
25
States / cities
Sheffield, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Compliance With Medical Testing Guidelines

NCT02430948
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Prostate Cancer, Colon Cancer, Lung Cancer
Interventions
Color-coded materials, Academic detailing, Standard support, No academic detailing
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
30 Years to 89 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

A Study of Surgery and Radiotherapy in People With Breast Cancer

NCT07053085
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions
Lumpectomy or mastectomy, Radiotherapy, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs
Procedure · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)

NCT05374915
View directory record Official record
Conditions
Cutaneous Breast Cancer
Interventions
REM-001 photodynamic therapy
Combination Product
Lead sponsor
Kintara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Not applicable Interventional

Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors

NCT00903474
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Cancer Survivor, Cognitive/Functional Effects, Depression, Psychosocial Effects of Cancer and Its Treatment
Interventions
questionnaire administration, study of socioeconomic and demographic variables, CAM exercise therapy, psychosocial assessment and care, quality-of-life assessment, stress management therapy
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
50 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

NCT00650910
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, Digoxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting Not applicable Interventional

Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer

NCT04362826
View directory record Official record
Conditions
Breast Cancer
Interventions
Novel probiotic, Placebo
Biological · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478
View directory record Official record
Conditions
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
Interventions
HER3-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel

NCT05751668
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
Interventions
Paclitaxel, Monosialotetrahexosylganglioside, Questionnaire Administration, Quality-of-life assessment, Placebo Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
33
States / cities
Irvine, California • Orange, California • Clearwater, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Precise Oncology Interventions in Nutrition and Training (OnPoint)

NCT06534918
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma
Interventions
Fitbit, Nutrition Course: Group Sessions, Physical Activity Program: Group Sessions, Nutrition Course: One on One Sessions with Registered Dietitian, Physical Activity Program: One on One Sessions with an Exercise Physiologist, Nutrition and Physical Activity Prescription
Other · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

High Dose Vitamin D vs Standard Dose Vitamin D Study

NCT01988090
View directory record Official record
Conditions
Breast Cancer
Interventions
800 IU Vitamin D Supplement, 50,000 IU Vitamin D supplement
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 1 Interventional Results available

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

NCT02751528
View directory record Official record
Conditions
Cancer
Interventions
ETBX-021
Biological
Lead sponsor
NantBioScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
El Segundo, California • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 20, 2026, 5:28 AM EDT